Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Table 1.

Socio demographic, type of HAART, baseline clinical and laboratory characteristics of study participants stratified by treatment groups.

More »

Table 1 Expand

Figure 1.

Comparison of incidence (Figure 1A) and severity grade of DILI in study participants stratified by treatment groups: HIV patients without TB co-infection (Arm-1) treated with efavirenz based HAART alone, TB-HIV co-infected patients with CD4 count ≤ 200 cells/μL treated with concomitant anti-TB and HAART therapy (Arm-2), TB-HIV co-infected patients with CD4 count >200 cells/μL treated with anti-TB therapy alone (Arm-3) and TB patients without HIV co-infection treated anti-TB therapy alone (Arm-4).

Figure 1B indicates severity grade distribution among the total 159 DILI cases.

More »

Figure 1 Expand

Table 2.

Comparison on incidence, type and severity grade of antiretroviral and/or antituberculosis DILI stratified by type of disease and treatment groups.

More »

Table 2 Expand

Figure 2.

Distribution of the different types of liver injuries (hepatocellular, cholestatic and mixed type) that were observed in each treatment group (Figure 2A) and stratified by severity grade (Figure 2B): HIV patients without TB co-infection (Arm-1) treated with efavirenz based HAART alone, TB-HIV co-infected patients with CD4 count ≤ 200 cells/μL treated with concomitant anti-TB and HAART therapy (Arm-2), TB-HIV co-infected patients with CD4 count >200 cells/μL treated with anti-TB therapy alone (Arm-3) and TB patients without HIV co-infection treated anti-TB therapy alone (Arm-4).

More »

Figure 2 Expand

Figure 3.

Kaplan–Meier curves to estimate cumulative hazard for the development of DILI stratified by type of treatment groups: HIV patients without TB co-infection (Arm-1) treated with efavirenz based HAART alone, TB-HIV co-infected patients with CD4 count ≤ 200 cells/μL treated with concomitant anti-TB and HAART therapy (Arm-2), TB-HIV co-infected patients with CD4 count >200 cells/μL treated with anti-TB therapy alone (Arm-3) and TB patients without HIV co-infection treated anti-TB therapy alone (Arm-4).

More »

Figure 3 Expand

Table 3.

Univariate and Multivariate Cox proportional regression analysis to show the risk factors for developing DILI. HR = hazard ratio.

More »

Table 3 Expand